Target intelligence / Profile preview

TP53-induced glycolysis and apoptosis regulator (TIGAR) (TIGAR)

Target
TIGAR
Molecular classification
Enzyme, Phosphatase
01

Overview

TP53-induced glycolysis and apoptosis regulator (TIGAR) is a p53-inducible enzyme that plays a pivotal role in coordinating cellular metabolism and antioxidant responses (UniProt Q9NQ88). It functions as a fructose-2,6-bisphosphatase, which lowers the levels of fructose-2,6-bisphosphate, thereby inhibiting glycolysis and redirecting glucose-6-phosphate into the pentose phosphate pathway (PPP) (Bensaad et al., 2006, PMID: 16439209). This metabolic redirection increases the production of NADPH and reduced glutathione, which are essential for scavenging reactive oxygen species (ROS) and protecting cells from oxidative damage (Lee et al., 2014, PMID: 24711453). In the context of oncology, TIGAR is frequently overexpressed in various tumors, where it promotes cell survival and resistance to apoptosis induced by chemotherapy or radiation (Tang et al., 2021, PMID: 33854974). Consequently, TIGAR is considered a promising therapeutic target, with strategies focusing on the use of antisense oligonucleotides or siRNA to degrade TIGAR mRNA and sensitize cancer cells to oxidative stress (Wanka et al., 2012, PMID: 22825330). Beyond cancer, TIGAR's role in modulating ROS has implications in ischemia-reperfusion injury and neurodegenerative diseases, where its regulation may offer cytoprotective benefits (Zhou et al., 2016, PMID: 27050158). Current research is actively exploring small molecule inhibitors and RNA-based therapies to modulate TIGAR activity for clinical applications.

Other names
C12orf5Fructose-2,6-bisphosphatase TIGARTP53-induced glycolysis and apoptosis regulator
02

Mechanism of action

Degradation of TIGAR mRNA via RNA interference or antisense mechanisms to deplete the TIGAR protein, leading to increased glycolytic flux, reduced antioxidant capacity, and elevated reactive oxygen species (ROS) levels.

03

Biological functions

Glycolysis regulationPentose phosphate pathwayAntioxidant defenseApoptosis inhibitionCell survival
04

Disease associations

CancerIschemia-reperfusion injuryNeurodegenerative disease
05

Safety considerations

Potential for systemic oxidative stressImpairment of normal metabolic fluxOff-target effects on healthy tissues requiring ROS protection (e.g., neurons, cardiomyocytes)
06

Interacting drugs

TIGAR siRNA

1 more in the full profile.

07

Biomarkers

TIGAR mRNA expression levelsp53 mutation statusIntracellular ROS levels

Beyond the preview

Go deeper on TP53-induced glycolysis and apoptosis regulator (TIGAR) (TIGAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TP53-induced glycolysis and apoptosis regulator (TIGAR) (TIGAR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call